https://doi.org/10.55788/dcb5e7fe
In a session on finding success in vascular access in dialysis patients, Dr Vandana Niyyar (Emory University, GA, USA) asked: “What do we mean when we say we want success? For me, that means providing the right access to the right patient, at the right time, for the right reasons. And then, once we define it, how can we achieve it and maintain it in the long term?” [1].
Dialysis has worse survival outcomes than invasive cancers, and there is often a discrepancy between what’s most important to the patient and to the clinician. Vascular access needs to be individualised to the patient, and patients need to be active decision-makers in their care. Patient education is associated with a 2-fold increase in the patient choosing arteriovenous fistula or arteriovenous graft.
Dr Niyyar reviewed strategies to optimise functional access as a nephrologist. She highlighted vessel preservation and timely referrals. At the nephrology level, doctors must appropriately refer patients to surgery. At Emory, her team was able to institute an automatic notification system for a nephrology consult for anyone scheduled to receive a peripherally inserted central catheter (PICC) line. Understanding all line options for specific vascular access is necessary, and institutional guidelines for treatment and follow-up are recommended.
Dr Niyyar’s team trained front-line haemodialysis staff to assess fistulas for maturity and use ultrasound to guide cannulation at Emory dialysis. This included 4 outpatient units and 150 patients. Diameter measurements were at 2 cm, 4 cm, and 6 cm from the anastomosis. At 4–6 weeks, maturity was examined, and if mature, scheduled for cannulation. Overall, 40 patients were cannulated, and there was only 1 case of infiltration. Ultrasound was useful for assessing maturity and doing the procedure, but Dr Niyyar stressed this is an adjunct — not a replacement — for physical examination.
- Niyyar VD. Keys to Success in Managing Vascular Access in Dialysis Patients. ASN Kidney Week 2023, 2–5 November, Philadelphia, PA, USA.
Copyright ©️2023 Medicom Medical Publishers
Posted on
Previous Article
« Patient care technicians improve haemodialysis patient outcomes Next Article
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk »
« Patient care technicians improve haemodialysis patient outcomes Next Article
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk »
Table of Contents: ASN 2023
Featured articles
Patient care technicians improve haemodialysis patient outcomes
Sparsentan outperforms irbesartan for treatment of IgAN
Chronic Kidney Disease
Aldosterone synthase inhibition reduces albuminuria in CKD
Low doses of zibotentan with dapagliflozin improve albuminuria in patients with CKD
Spironolactone failed to reduce major adverse cardiac effects in patients with CKD on haemodialysis
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk
Renal Replacement Therapy
New approaches to successful vascular access
Patient care technicians improve haemodialysis patient outcomes
Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery
A systems approach to kidney transplantation disappoints
Glomerular Disease
Obinutuzumab attenuates kidney decline in lupus nephritis
Clinical benefits of sparsentan for patients with FSGS
Sparsentan outperforms irbesartan for treatment of IgAN
Rare or Genetic Kidney Disease
Small molecule PGE1 shows promise for nephronophthisis treatment in vitro and in vivo
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com